Wegovy is a genuine breakthrough for the 1.2 million people in England living with cardiovascular disease — cutting the risk of heart attacks and strokes by 20% on top of existing treatments. The SELECT trial proved this benefit kicks in before significant weight loss even occurs, meaning the drug works directly on the heart. Expanding NHS access to semaglutide is smart, cost-effective prevention that saves lives.
Wegovy is no magic bullet — 85% of people who stop taking it regain the weight, and long-term safety data simply doesn't exist yet. Treating obesity with expensive weekly injections ignores the root causes driving the health crisis and risks sidelining the lifestyle changes that actually deliver lasting results. Lifestyle medicine cuts coronary artery disease risk by over 80% without the side effects or the staggering cost.
© 2026 Improve the News Foundation.
All rights reserved.
Version 6.18.0